Quantcast

Latest Non-small cell lung carcinoma Stories

2014-09-15 16:28:12

Multidisciplinary team composed of six organizations awarded $20,000 for groundbreaking work in mesothelioma and non-small cell lung cancer SYDNEY, Sept. 15, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that, together with the Asbestos Disease Research Institute (ADRI), it has received the 2014 Cancer Institute New...

2014-09-12 12:25:16

DARMSTADT, Germany, September 12, 2014 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, announced today that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC). Luciano Rossetti, Global Head of Research & Development at the biopharmaceutical division, said: "While the data...

2014-08-20 23:02:19

New research report “Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, the NSCLC Market in top 8 developed nations is predicted to see a 6.6% CAGR through 2020. London, UK (PRWEB) August 20, 2014 The non-small cell lung cancer (NSCLC) market value is expected to increase considerably in the offing...

2014-08-18 23:02:59

The anti-cancer drug Xalkori® is being investigated by the ECOG-ACRIN Cancer Research Group in E4512, a phase III trial. Philadelphia, PA (PRWEB) August 18, 2014 People diagnosed with early-stage non-squamous non-small cell lung cancer whose tumors have an altered ALK gene now have the opportunity to participate in a new phase III clinical trial, ECOG-ACRIN announced today. The trial will determine if Xalkori® (generic name crizotinib, an ALK-inhibitor), when used after...

2014-08-12 11:57:56

Wiley A new analysis confirms that US lung cancer rates are declining overall, but it also uncovers previously unrecognized trends related to cancer subtype, sex, race/ethnicity, and age. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings provide a more accurate picture of the state of lung cancer in the country and will help researchers in their ongoing efforts to monitor the population's lung health. Overall, lung cancer rates are...

2014-07-28 04:21:34

HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data from plasma samples to guide the use of IRESSA for non-small cell lung cancer patients - New blood test will build on QIAGEN's FDA-approved therascreen EGFR test and is planned to run on Rotor-Gene Q, member of the QIAsymphony family of automated instruments -...

2014-07-15 23:14:44

Targeted therapy for pancreatic cancer is based on personalized medicine approach Somerville, Massachusetts (PRWEB) July 15, 2014 ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that Tozaride, the Company's lead candidate, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of pancreatic cancer. Pancreatic cancer is responsible for significant cancer...

2014-07-09 08:27:52

VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced today that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP). The research funded by this award will be conducted in collaboration with the University of British Columbia, the Vancouver Prostate Centre and...

2014-07-03 12:23:38

TGEN Lung cancer patients could especially benefit from new ‘QTA’ technique Lung cancer patients could receive more precise treatment, and their progress could be better tracked, using a new high-tech method of non-invasive medical imaging analysis, according to a study published today by the journal PLOS ONE. Genetic changes increasingly are recognized as driving cancer development. But obtaining evidence of these changes usually requires a biopsy, which can be problematic for...

2014-07-01 16:30:23

Report Stems From National Grassroots Advocacy To Require New Strategic Plans Of Action To Address Deadliest Cancers WASHINGTON, July 1, 2014 /PRNewswire-USNewswire/ -- Today the National Cancer Institute (NCI), led by Harold Varmus, MD, presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer, one of the most lethal forms of the disease. The report, entitled "Scientific Framework for Small Cell Lung Cancer (SCLC)" was...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.